The Justice Department changed its policy on foreign corruption cases, which might have put an end to investigations into the ...

Given the advantages over its rivals, Regeneron is hopeful its bispecific antibody will become the new standard of care for ...

XtalPi has accrued a number of Big Pharma partners over the years, including Eli Lilly, which struck a $250 million deal in 2023 to use XtalPi’s tech to identify potential drug candidates that Lilly ...

Regeneron Pharmaceuticals said on Wednesday the U.S. Food and Drug Administration has approved its drug for a type of blood ...

New PICCOLO trial analyses showed that mirvetuximab soravtansine achieved 52% response rates and 27-month overall survival in ...

That’s where anti-inflammatory therapeutics come into play, offering hope for millions of people living with chronic inflammation. The global anti-inflammatory therapeutics market size was $98,026 ...

Johnson & Johnson JNJ, under its Innovative Medicine segment, markets several multi-million-dollar drugs that cover a broad ...

A history of Johnson & JohnsonUnited under the common name of J&J, Janssen is now split into three different businesses – Janssen Research & Development, Janssen Healthcare Innovation and ...

Merck announced ACIP voted to recommend Enflosnia (clesrovimab-cfor) as a treatment option for RSV in infants younger than 8 months of age who are born during or entering their first RSV season.

As scientific breakthroughs continue to transform medicine in 2025, companies across the biotech and pharmaceutical sectors ...

Another BCMA-targeted agent has arrived for the treatment of multiple myeloma. | After a delay, Regeneron’s BCMA-directed ...

Johnson & Johnson is set to unveil its Q2 results in the upcoming month, and analysts expect its profitability to observe a ...